Substance / Medication

Mosunetuzumab

Overview

Active Ingredient
mosunetuzumab
RxNorm CUI
2625122
Labeler: Genentech, Inc.Updated: 2025-12-19T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Dosage and Administration (2.1 2.4) Warnings and Precautions (5.1) [seeandand] Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO VELO. Initiate treatment with the LUNSUMIO VELO step-up dosing schedule to reduce the risk of CRS.

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch Francesc, Kuruvilla John, Vassilakopoulos Theodoros P et al. · Clin Lymphoma Myeloma Leuk · 2024
PMID: 37981564Meta-Analysis
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.
Thiruvengadam Swetha Kambhampati, Popplewell Leslie L, Herrera Alex F et al. · Br J Haematol · 2026
PMID: 41254806TrialFull text (PMC)
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.
Li Chi-Chung, Bender Brendan, Wilkins Justin et al. · Clin Pharmacol Ther · 2025
PMID: 39328022TrialFull text (PMC)
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn Laurie H, Bartlett Nancy L, Matasar Matthew J et al. · Blood · 2025
PMID: 39447094TrialFull text (PMC)
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Chong Elise A, Penuel Elicia, Napier Ellen B et al. · Blood Adv · 2025
PMID: 39571171TrialFull text (PMC)
Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1.
Goto Hideki, Kumode Takahiro, Mishima Yuko et al. · Int J Clin Oncol · 2025
PMID: 39652156TrialFull text (PMC)
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.
Westin Jason, Phillips Tycel J, Mehta Amitkumar et al. · Blood Adv · 2025
PMID: 39908481TrialFull text (PMC)
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.
Danilov Alexey V, Kambhampati Thiruvengadam Swetha, Linton Kim et al. · Blood Adv · 2025
PMID: 40472301TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mosunetuzumab (substance)
SNOMED CT
278181000202107
UMLS CUI
C4763385
RxNorm CUI
2625122
Labeler
Genentech, Inc.

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.